CalciMedica (CALC) grants director 10,000 stock options through 2036

Rhea-AI Filing Summary

CalciMedica, Inc. (CALC) reported that director Allan Shaw received a grant of 10,000 Director Stock Options to purchase common stock. The options have an exercise price of $0.6131 per share and expire on August 18, 2036. According to the vesting terms, 1/12 of the shares vest in equal monthly installments over one year following the grant date, and the award will in any case be fully vested on the date of CalciMedica’s 2027 annual meeting of stockholders. Following this grant, Shaw holds 10,000 options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Shaw Allan

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (Right to Buy) F1	10,000	$0.00	$0.00

Holdings After Transaction: Director Stock Option (Right to Buy) — 10,000 shares (Direct)

Footnotes (1)

1. F1. 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following the date of grant, provided that the option will in any case be fully vested on the date of the 2027 annual meeting of stockholders of CalciMedica, Inc.

Key Figures

Director Stock Options Granted: 10,000 options Exercise Price: $0.6131 per share Expiration Date: August 18, 2036 +4 more

7 metrics

Director Stock Options Granted 10,000 options Director Stock Option (Right to Buy) granted to Allan Shaw on 2026-08-19

Exercise Price $0.6131 per share Conversion or exercise price of the Director Stock Options

Expiration Date August 18, 2036 Expiration date of the 10,000 Director Stock Options

Underlying Common Shares 10,000 shares Underlying CalciMedica, Inc. common stock for the options granted

Options Owned After Transaction 10,000 options Total derivative securities owned directly by Allan Shaw following the grant

Vesting Schedule 1/12 monthly over 1 year Equal monthly installments over one year following grant date

Full Vesting Outside Date 2027 annual meeting of stockholders Option will in any case be fully vested on this meeting date

Key Terms

Director Stock Option, derivative securities, vesting, annual meeting of stockholders

4 terms

Director Stock Option financial

"security_title: Director Stock Option (Right to Buy)"

derivative securities financial

"The award is coded as an acquisition of derivative securities"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

vesting financial

"1/12th of the shares subject to the option vest in equal monthly"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of stockholders financial

"fully vested on the date of the 2027 annual meeting of stockholders"

FAQ

What insider transaction did CALC director Allan Shaw report on this Form 4?

Allan Shaw reported a grant of 10,000 Director Stock Options for CalciMedica, Inc. common stock. The award is coded as an acquisition (grant/award) of derivative securities and represents his direct holdings after the transaction.

What is the exercise price of the options granted to Allan Shaw at CALC?

The options granted to Allan Shaw have an exercise price of $0.6131 per share of CalciMedica, Inc. common stock. This is the price per share at which he may purchase the underlying common stock upon exercise of the options.

How many CalciMedica (CALC) options does Allan Shaw hold after this transaction?

After this grant, Allan Shaw holds 10,000 Director Stock Options directly. The Form 4 states a total of 10,000 derivative securities owned following the reported acquisition, all relating to CalciMedica, Inc. common stock.

What are the vesting terms of Allan Shaw’s CALC stock option grant?

The filing states that 1/12 of the shares vest in equal monthly installments over one year following the grant date. It also provides that the option will be fully vested on the date of CalciMedica’s 2027 annual meeting of stockholders, regardless of the monthly schedule.

When do Allan Shaw’s CALC director stock options expire?

The options granted to Allan Shaw expire on August 18, 2036. This expiration date applies to the 10,000 Director Stock Options reported, subject to the vesting schedule and the full vesting by the 2027 annual meeting of stockholders.

Is Allan Shaw’s CALC Form 4 transaction under a Rule 10b5-1 plan?

The document-level Rule 10b5-1 checkbox is not affirmed (set to false), and the filing does not state that the grant occurred pursuant to a Rule 10b5-1 trading plan. The transaction is reported simply as a grant or award acquisition.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/21/2026 - 06:49 PM Accepted by SEC EDGAR 08/21/2026 - 06:48 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shaw Allan

(Last) (First) (Middle)

C/O CALCIMEDICA, INC.

505 COAST S. BLVD. #202

(Street)

LA JOLLA CALIFORNIA 92037

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CalciMedica, Inc. [ CALC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	$0.6131	08/19/2026		A		10,000		(1)	08/18/2036	Common Stock	10,000	$0	10,000	D

Explanation of Responses:

1. 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following the date of grant, provided that the option will in any case be fully vested on the date of the 2027 annual meeting of stockholders of CalciMedica, Inc.

	/s/ John Dunn, Attorney-in-Fact	08/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)